Virtual, Augmented, and Mixed Reality Technologies in Neurosurgical Training: Enhancing Skills and Surgical Outcomes: A Systematic Review.

J Surg EducJul 31, 2026 (epub)
Clinical ResearchNeurosurgery

Tayebeh Azarmehr, Fatemeh Pouladkhay, Jebraeil Farzi et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the impact of virtual reality (VR), augmented reality (AR), and mixed reality (MR) on neurosurgical education. It included studies involving neurosurgeons, fellows, residents, and medical students. The review found that VR was used for surgical simulation in all studies, with 52% reporting improved training effectiveness and 44% improved technical proficiency.

Key findings

  • VR was used for surgical simulation in 100% of studies and anatomical education in 62.5%.
  • AR applications included preoperative planning (40%) and intraoperative support (30%).
  • 52% of studies reported improved training effectiveness and 44% improved technical proficiency.

Why it matters

The integration of VR, AR, and MR in neurosurgical training could significantly enhance surgical skills and educational outcomes, potentially leading to better patient care and surgical precision.

Source

PubMed · PMID 42542047

Published in J Surg Educ. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.